AFFIVANT
Affivant is committed to the development of novel immuno-oncology techniques that will stimulate and enable the innate immune system to fight cancer.
AFFIVANT
Social Links:
Industry:
Biotechnology Market Research Oncology
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.affivant.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
U.S. Server Location
Similar Organizations
Abingworth
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Actym Therapeutics, Inc.
Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Apeximmune Therapeutics
Apeximmune Therapeutics engages in the discovery and development of novel biologics that modulate the immune system.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
CDR-Life AG
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
Exacis Biotherapeutics
Exacis is a development-stage immuno-oncology company focused on harnessing the human immune system to cure cancer.
Haemalogix
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.
NBE-Therapeutics
NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Official Site Inspections
http://www.affivant.com
- Host name: 38.33.167.120
- IP address: 38.33.167.120
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Affivant"
Affivant - LinkedIn
Affivant is dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer. Our innovative bi-specific innate cell engagers are designed ...See details»
Affivant - Products, Competitors, Financials, Employees, …
Jul 4, 2023 Affivant is a biotechnology company. The company is developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer. Its bi …See details»
Affivant Sciences Ltd. - Drug pipelines, Patents, Clinical trials
Affivant disclosed that it expects to initiate phase 1 clinical trials in 2023. As of the end of 2022, Affimed had completed work on and/or handed over all product candidates covered by the …See details»
Affivant - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Affivant is a Basel, Switzerland based biotech company developing innate …See details»
Affivant Sciences: The Venture Leader Biotech innovating the use …
May 15, 2023 Meet Zoë Johnson, CSO of Affivant Sciences. The startup, seeded by Roivant, develops novel bispecific tetravalent monoclonal antibodies in an effort to engage the innate …See details»
Affivant - VentureRadar
Affivant, a Roivant Sciences company, is dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer. ... Dansk Biotek …See details»
Affivant to Present Data on AFVT-2101 at 37th Annual
Nov 10, 2022 NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology... Affivant …See details»
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting
Nov 10, 2022 NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology …See details»
Affivant Sciences GmbH - startup.ch
Affivant's lead asset, AFVT-2101, binds to Folate Receptor alpha, a tumor target that has been clinically validated for ovarian cancer. The ultra high affinity, selective, CD16A engagement of …See details»
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of …
Nov 10, 2022 NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology …See details»
Affivant - Contacts, Employees, Board Members, Advisors & Alumni
Affivant is committed to the development of novel immuno-oncology techniques that will stimulate and enable the innate immune system. Search Crunchbase. Start Free Trial . Chrome …See details»
Affivant Sciences GmbH - Venturelab
Oct 27, 2020 Affivant's lead asset, AFVT-2101, binds to Folate Receptor alpha, a tumor target that has been clinically validated for ovarian cancer. The ultra high affinity, selective, CD16A …See details»
Affivant - LinkedIn
Affivant | 685 followers on LinkedIn. Affivant is dedicated to developing novel immune-oncology approaches to enable the immune system to fight cancer. | Affivant is dedicated to developing …See details»
Affivant - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Affivant is committed to the development of novel immuno-oncology techniques that will stimulate and enable the innate immune system. New. Resources. ... Log In. Experience the new …See details»
Targeted innate immune engagement for broad cancer-patient
Affivant’s first program is AFVT-2101, a potentially first-in-class tetravalent bispecific antibody built with Affimed’s Redirected Optimized Cell Killing (ROCK) platform (Fig. 1).See details»
Affivant on LinkedIn: Affivant is proud to present new data from …
Affivant is proud to present new data from our lead program, AFVT-2101, at the upcoming American Association for Cancer Research Annual Meeting 2023. Poster #1811 on Monday …See details»
Affivant - Crunchbase
Affivant is committed to the development of novel immuno-oncology techniques that will stimulate and enable the innate immune system. Search Crunchbase. Start Free Trial . Chrome …See details»
Affivant - Updates, News, Events, Signals & Triggers - Crunchbase
Affivant is committed to the development of novel immuno-oncology techniques that will stimulate and enable the innate immune system. New. Resources. ... Experience the new Crunchbase, …See details»
Registration forms for non-profits - Alberta.ca
Use these forms to keep your non-profit organization or society registration up to date. Explore pages in: Non-profit incorporation steps and forms. Incorporation forms; Registration forms …See details»